With Hopeful Interim Data, Ultragenyx Bets On GeneTx, Angelman Syndrome Candidate

 
• By Joseph Haas

Ultragenyx is buying its Angelman syndrome partner GeneTx for $75m on the heels of an interim Phase I/II readout that shows signs of clinical activity and appears to resolve earlier safety worries.

Ultragenyx hopes it and GeneTx have found right genomic approach to Angelman syndrome

More from Rare Diseases

More from Scrip